title: Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein.
abstract: Neutralizing antibodies against therapeutic proteins can be potentially harmful if the antibody blocks not only the therapeutic activities of the therapeutic protein but also the normal functions of the endogenous counterpart. Detection of the neutralizing anti-therapeutic protein antibodies generally relies on bioassays measuring changes in the biologic activity of the therapeutic protein triggered by the presence of the antibody. Most of the bioassays, particularly the cell-based in vitro assays, fail to detect neutralizing anti-therapeutic protein antibodies when the remaining therapeutic protein level in the assay samples is high. The remaining therapeutic protein, either a free molecule or an immune complex with anti-therapeutic protein antibodies, can inhibit the neutralizing activity of the antibody and prevent detection. We describe the development of a procedure that uses acid dissociation and affinity adsorption to remove therapeutic protein from assay samples. With this procedure, we can detect the presence of neutralizing anti-therapeutic protein antibodies from samples containing high levels of therapeutic protein.
authors.affiliation: Department of Clinical Immunology, Amgen Inc, One Amgen Center Drive, M/S 30E-3-C, Thousand Oaks, CA 91320, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Lofgren
authors.forename: Iwona
authors.initials: I
authors.lastname: Wala
authors.forename: Eugen
authors.initials: E
authors.lastname: Koren
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: Shuqian
authors.initials: S
authors.lastname: Jing
mesh_terms: D000906:Antibodies / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000097:blood; D000936:Antigen-Antibody Complex / Q000097:blood / Q000302:isolation & purification; D002460:Cell Line; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007163:Immunosorbent Techniques; D066298:In Vitro Techniques; D016209:Interleukin-8 / Q000096:biosynthesis; D009500:Neutralization Tests / Q000379:methods*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors / Q000276:immunology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000097:blood* / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D016209:Interleukin-8; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins